Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 5/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23537564 | 0.95 | ALOX15 (0.36) | ALOX15SMN1; SMN2WNT3ATNKS2 | |
| SCHEMBL23537215 | 0.84 | ALOX15 (0.49) | ALOX15SMN1; SMN2 | |
| SCHEMBL23537351 | 0.82 | WNT3A (0.33) | WNT3ATNKS2 | |
| SCHEMBL23537494 | 0.77 | WNT3A (0.33) | ALOX15SMN1; SMN2WNT3ATNKS2 | |
| SCHEMBL30022683 | 0.69 | SMN1; SMN2 (0.45) | ALOX15SMN1; SMN2 | |
| SCHEMBL23537285 | 0.69 | SMN1; SMN2 (0.45) | ALOX15SMN1; SMN2 | |
| SCHEMBL23537222 | 0.69 | PARP1 (0.49) | TNKS2 | |
| SCHEMBL29824229 | 0.69 | PARP1 (0.49) | TNKS2 | |
| SCHEMBL23537289 | 0.68 | SMN1; SMN2 (0.38) | ALOX15SMN1; SMN2WNT3ATNKS2 | |
| SCHEMBL23537497 | 0.68 | CYP2D6 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108906-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-04-06 | — | — | US | disclosed |
| EP-4076648-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087486-A | Substituted bicyclic and tricyclic ureas and amides, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021127356-A1 | Substituted Bicyclic and Tricyclic Ureas and Amides, Analogues Thereof, and Methods Using Same | ARBUTUS BIOPHARMA, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108906-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | DDC, CDA, HMBS | ALOX15 4219/4885SMN1; SMN2 4530/4885WNT3A 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.